Genetic advances in inflammatory bowel disease

Current Treatment Options in Gastroenterology

Volumn 9, Issue 3, 2006, Pages 191-200

  Cho, Judy ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CASPASE RECRUITMENT DOMAIN PROTEIN 15; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; PATTERN RECOGNITION RECEPTOR; PEPTIDOGLYCAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

CHROMOSOME 16; CHROMOSOME 5Q; CLINICAL PRACTICE; CROHN DISEASE; DISEASE ASSOCIATION; ENTERITIS; ENVIRONMENTAL FACTOR; GENE ACTIVITY; GENE EXPRESSION; GENE FUNCTION; GENE INTERACTION; GENE LOCATION; GENE MUTATION; GENETIC DISORDER; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; INNATE IMMUNITY; MEDICAL RESEARCH; NONHUMAN; PATHOGENESIS; PATIENT CODING; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

EID: 33744962883     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-006-0038-z     Document Type: Review

References (54)

1. Hugot JP, Laurent-Puig P, Gower-Rousseau C, et al.: Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 1996, 379:821-823.
2. Girardin SE, Boneca IG, Viala J, et al.: Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003, 278:8869-8872.
3. Inohara N, Ogura Y, Fontalba A, et al.: Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem 2003, 278:5509-5512.
4. Otte JM, Rosenberg IM, Podolsky DK: Intestinal myofibroblasts in innate immune responses of the intestine. Gastroenterology 2003, 124:1866-1878.
5. Ogura Y, Inohara N, Benito A, et al.: Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem 2001, 276:4812-4818.
6. Lala S, Ogura Y, Osborne C, et al.: Crohn's disease and the NOD2 gene: a role for paneth cells. Gastroenterology 2003, 125:47-57.
7. Kobayashi KS, Chamaillard M, Ogura Y, et al.: Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005, 307:731-734.
8. Li J, Moran T, Swanson E, et al.: Regulation of IL-8 and IL-1beta expression in Crohn's disease associated NOD2/CARD15 mutations. Hum Mol Genet 2004, 13:1715-1725.
9. Hugot JP, Chamaillard M, Zouali H, et al.: Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001, 411:599-603.
10. Ogura Y, Bonen DK, Inohara N, et al.: A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001, 411:603-606.
11. Lesage S, Zouali H, Cezard JP, et al.: CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 2002, 70:845-857.
12. Bonen DK Ogura Y, Nicolae DL, et al.: Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology 2003, 124:140-146.
13. Chamaillard M, Philpott D, Girardin SE, et al.: Gene-environment interaction modulated by allelic heterogeneity in inflammatory diseases. Proc Natl Acad Sci U S A 2003, 100:3455-3460.
14. Gutierrez O, Pipaon C, Inohara N, et al.: Induction of Nod2 in myelomonocytic and intestinal epithelial cells via nuclear factor-kappa B activation. J Biol Chem 2002, 277: 41701-41705.
15. Economou M, Trikalinos TA, Loizou KT, et al.: Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol 2004, 99:2393-2404.
16. Kugathasan S, Loizides A, Babusukumar U, et al.: Comparative phenotypic and CARD15 mutational analysis among African American, Hispanic, and white children with Crohn's disease. Inflamm Bowel Dis 2005, 11:631-638.
17. Inoue N, Tamura K, Kinouchi Y, et al.: Lack of common NOD2 variants in Japanese patients with Crohn's disease. Gastroenterology 2002, 123:86-91.
18. Holler E, Rogler G, Herfarth H, et al.: Both donor and recipient NOD2/ CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood 2004, 104:889-894.
19. Pauleau AL, Murray PJ: Role of nod2 in the response of macrophages to toll-like receptor agonists. Mol Cell Biol 2003, 23:7531-7539.
20. Wehkamp J, Harder J, Weichenthal M, et al.: NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut 2004, 53:1658-1664.
21. Maeda S, Hsu LC, Liu H, et al.: Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science 2005, 307:734-738.
22. Netea MG, Kullberg BJ, de Jong DJ, et al.: NOD2 mediates anti-inflammatory signals induced by TLR2 ligands: implications for Crohn's disease. Eur J Immunol 2004, 34:2052-2059.
23. Uehara A, Yang S, Fujimoto Y, et al.: Muramyldipeptide and diaminopimelic acid-containing desmuramyl-peptides in combination with chemically synthesized Toll-like receptor agonists synergistically induced production of interleukin-8 in a NOD2- and NOD1-dependent manner, respectively, in human monocytic cells in culture. Cell Microbiol 2005, 7:53-61.
24. Watanabe T, Kitani A, Murray PJ, Strober W: NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol 2004, 5:800-808.
25. Girardin SE, Boneca IG, Carneiro LA, et al.: Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science 2003, 300:1584-1587.
26. McGovern DP, Hysi P, Ahmad T, et al.: Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease. Hum Mol Genet 2005, 14:1245-1250.
27. Vermeire S, Rutgeerts P: Current status of genetics research in inflammatory bowel disease. Genes Immun 2005, 6:637-645.
28. Lakatos PL, Lakatos L, Szalay F, et al.: Toll-like receptor 4 and NOD2/ CARD15 mutations in Hungarian patients with Crohn's disease: phenotype-genotype correlations. World J Gastroenterol 2005, 11:1489-1495.
29. Arbour NC, Lorenz E, Schutte BC, et al.: TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000, 25:187-191.
30. Lodes MJ, Cong Y, Elson CO, et al.: Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 2004, 113:1296-1306.
31. Gewirtz AT, Vijay-Kumar M, Brant SR, et al.: Dominant-negative TLR5 polymorphism reduces adaptive immune response to flagellin and negatively associates with Crohn's disease. Am J Physiol Gastrointest Liver Physiol 2006, In press.
32. Rioux JD, Daly MJ, Silverberg MS, et al.: Genetic variation in the 5q31 cytokine gene duster confers susceptibility to Crohn disease. Nat Genet 2001, 29:223-228.
33. Giallourakis C, Stoll M, Miller K, et al.: IBD5 is a general risk factor for inflammatory bowel disease: replication of association with Crohn disease and identification of a novel association with ulcerative colitis. Am J Hum Genet 2003, 73:205-211.
34. Waller S, Tremelling M, Bredin F, et al.: Evidence for association of OCTN genes and IBD5 with ulcerative colitis. Gut 2005, In press.
35. Peltekova VD, Wintle RF, Rubin LA, et al.: Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet 2004, 36:471-475.
36. Armuzzi A, Ahmad T, Ling KL, et al.: Genotype-phenotype analysis of the Crohn's disease susceptibility haplotype on chromosome 5q31. Gut 2003, 52:1133-1139.
37. Vermeire S, Pierik M, Hlavaty T, et al.: Association of organic cation transporter risk haplotype with perianal penetrating Crohn's disease but not with susceptibility to IBD. Gastroenterology 2005, 129:1845-1853.
38. Newman B, Gu X, Wintle R, et al.: A risk haplotype in the Solute Carrier Family 22A4/22A5 gene cluster influences phenotypic expression of Crohn's disease. Gastroenterology 2005, 128:260-269.
39. Noble CL, Nimmo ER, Drummond H, et al.: The contribution of OCTN1/2 variants within the IBD5 locus to disease susceptibility and severity in Crohn's disease. Gastroenterology 2005, 129:1854-1864.
40. Palmieri O, Latiano A, Valvano R, et al.: Variants of OCTN1-2 cation transporter genes are associated with both Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther 2006, 23:497-506.
41. Stoll M, Corneliussen B, Costello CM, et al.: Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet 2004, 36:476-480.
42. Hampe J, Schreiber S, Shaw SH, et al.: A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. Am J Hum Genet 1999, 64:808-816.
43. Wakabayashi M, Ito T, Mitsushima M, et al.: Interaction of lp-dlg/ KIAA0583, a membrane-associated guanylate kinase family protein, with vinexin and beta-catenin at sites of cell-cell contact. J Biol Chem 2003, 278:21709-21714.
44. Newman WG, Gu X, Wintle RF, et al.: DLG5 variants contribute to Crohn disease risk in a Canadian population. Hum Mutat 2006, 27:353-358.
45. Stokkers PC, Reitsma PH, Tytgat GN, van Deventer SJ: HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis. Gut 1999, 45:395-401.
46. Bonen DK, Cho JH: The genetics of inflammatory bowel disease. Gastroenterology 2003, 124:521-536.
47. Kontoyiannis D, Pasparakis M, Pizarro TT, et al.: Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999, 10:387-398.
48. Panwala CM, Jones JC, Viney JL: A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 1998, 161:5733-5744.
49. Langmann T, Moehle C, Mauerer R, et al.: Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology 2004, 127:26-40.
50. Yamada T, Takaoka AS, Naishiro Y, et al.: Transactivation of the multidrug resistance 1 gene by T-cell factor 4/beta-catenin complex in early colorectal carcinogenesis. Cancer Res 2000, 60:4761-4766.
51. Geick A, Eichelbaum M, Burk O: Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 2001, 276:14581-14587.
52. Dring MM, Goulding CA, Trimble VI, et al.: The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease [quiz]. Gastroenterology 2006, 130:341-348. Quiz 592.
53. Sugawara K, Olson TS, Moskaluk CA, et al.: Linkage to peroxisome proliferator-activated receptor-gamma in SAMP1/YitFc mice and in human Crohn's disease. Gastroenterology 2005, 128:351-360.
54. Lewis JD, Lichtenstein GR, Stein RB, et al.: An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol 2001, 96:3323-3328.